Articles by: Geisel Communications

Want to Know if You Need Lifestyle Changes to Slow Down Alzheimer’s? A Group of Williamstown Seniors May be Using Their Phones for Clues—The Berkshire Eagle

Read article—Karen Fortuna, assistant professor of community and family medicine, and Vedan Taplivana ’26, created an app for tracking Alzheimer’s progression. The app, called RealVision, tracks how users interact with their phones, noting such changes as disoriented eye movement, difficulty with typing, or needing more time to respond to prompts. “Some of these patterns are quite nuanced and may not be easily noticeable to the human eye in real time,” Fortuna said. “That’s where computational approaches can help by detecting patterns across many small signals over time.”

Procedure to Treat Type 2 Diabetes Helps Keep Off Weight After Patients Stop GLP-1 Drugs—Reuters

Red article—Features a clinical trial led by Shelby Sullivan, a professor of medicine, reporting that an outpatient procedure used to treat type 2 diabetes can help prevent people from regaining weight after discontinuing  GLP-1 drugs. “Finding a treatment that allows patients to stop these medications without weight regain or loss of metabolic benefit is a huge ​unmet need,” Sullivan said. (Similar coverage in New Hampshire Union Leader and HealthDay.)

Will Bargain-Basement Telehealth Visits Help Pharma Drive Drug Scripts?—STAT News

Read article—Quotes Steven Woloshin, MED ’96, a professor of health policy and clinical practice and co-director of The Dartmouth Institute’s Center for Medicine and Media, who cautions patients to question telehealth providers. “It seems like you’re getting a bargain, but you’re taking your eye off the prize, which is: Do I have something that should be treated with a pill? Will this pill help me? Will the benefits outweigh the harms?” Woloshin said.

Simple ‘Metabolic Reset’ Found to Prevent Weight Rebound After Discontinuing GLP-1 Drugs—The Independent

Read article—Shelby Sullivan, a professor of medicine, talks about the clinical trial she led showing that a minimally invasive procedure may help patients maintain weight loss after stopping GLP-1 drugs. The results will be presented May 4 at Digestive Disease Week 2026. “What’s particularly encouraging is that the benefit appears to increase over time rather than fade, and that it behaves like a drug in terms of dose response,” Sullivan said.